Should I buy or sell Inhibikase Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibikase Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IKT shares. View IKT analyst ratings or view top-rated stocks .

What is Inhibikase Therapeutics' stock price target for 2024?

1 brokers have issued twelve-month price objectives for Inhibikase Therapeutics' shares. Their IKT share price targets range from $27.00 to $27.00. On average, they predict the company's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 1,185.7% from the stock's current price. View analysts price targets for IKT or view top-rated stocks among Wall Street analysts .

How have IKT shares performed in 2024?

Inhibikase Therapeutics' stock was trading at $1.27 at the beginning of 2024. Since then, IKT shares have increased by 65.4% and is now trading at $2.10. View the best growth stocks for 2024 here .

When is Inhibikase Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our IKT earnings forecast .

How were Inhibikase Therapeutics' earnings last quarter?

Inhibikase Therapeutics, Inc. (NYSE:IKT) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.15. Inhibikase Therapeutics had a negative net margin of 5,886.15% and a negative trailing twelve-month return on equity of 107.54%.

When did Inhibikase Therapeutics' stock split?

Inhibikase Therapeutics's stock reverse split before market open on Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

When did Inhibikase Therapeutics IPO?

Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

How do I buy shares of Inhibikase Therapeutics?

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:IKT

Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free IKT Stock Alerts

$2.10

-0.03 (-1.41%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.04
▼
$2.15
50-Day Range: $1.93
▼
$2.68
52-Week Range: $0.79
▼
$4.35

Volume: 27,598 shs
Average Volume: 126,159 shs
Market Capitalization: $13.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.00

Get Inhibikase Therapeutics alerts:

Inhibikase Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,185.7% Upside
$27.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.71) to ($1.52) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.97 out of 5 stars

Medical Sector

799th out of 918 stocks

Biological Products, Except Diagnostic Industry

133rd out of 147 stocks

3.5

Analyst's Opinion

Consensus Rating
Inhibikase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Inhibikase Therapeutics has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for IKT.

0.0

Dividend Strength

Dividend Yield
Inhibikase Therapeutics does not currently pay a dividend.
Dividend Growth
Inhibikase Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IKT.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Inhibikase Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for IKT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.30% of the stock of Inhibikase Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 3.81% of the stock of Inhibikase Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inhibikase Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inhibikase Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inhibikase Therapeutics has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Inhibikase Therapeutics Stock (NYSE:IKT)

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

IKT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IKT Stock News Headlines

April 19, 2024 | americanbankingnews.com

Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 1.4%

April 18, 2024 | globenewswire.com

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 3, 2024 | markets.businessinsider.com

Inhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick Facts

April 3, 2024 | globenewswire.com

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

April 3, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progress

April 2, 2024 | finance.yahoo.com

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript

April 2, 2024 | finance.yahoo.com

Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 29, 2024 | finance.yahoo.com

Q4 2023 Inhibikase Therapeutics Inc Earnings Call

March 27, 2024 | globenewswire.com

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

March 7, 2024 | finance.yahoo.com

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

March 7, 2024 | globenewswire.com

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

March 7, 2024 | globenewswire.com

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

March 6, 2024 | markets.businessinsider.com

Buy Rating Backed by Promising Developments and Regulatory Confidence in Inhibikase’s Pipeline

March 5, 2024 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know

February 28, 2024 | globenewswire.com

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

February 21, 2024 | markets.businessinsider.com

Inhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial Standing

February 15, 2024 | finance.yahoo.com

Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now

February 10, 2024 | investing.com

Inhibikase Therapeutics Inc (IKT)

February 8, 2024 | msn.com

Inhibikase Discusses FDA Pathway for New Cancer Drug

February 7, 2024 | msn.com

Tenax Therapeutics, Equillium among healthcare movers

February 7, 2024 | finance.yahoo.com

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

February 6, 2024 | msn.com

New Strong Buy Stocks for February 6th

January 29, 2024 | finance.yahoo.com

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

January 22, 2024 | finance.yahoo.com

Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?

January 17, 2024 | msn.com

Inhibikase Therapeutics appoints Lees-Rolfe as CFO

See More Headlines

Receive IKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSE:IKT
CUSIP: N/A
CIK: 1750149
Web: www.inhibikase.com
Phone: 678-392-3419
Fax: N/A
Employees: 8
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.00
High Stock Price Target: $27.00
Low Stock Price Target: $27.00
Potential Upside/Downside: +1,185.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.5598)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,030,000.00
Net Margins: -5,886.15%
Pretax Margin: -7,290.80%
Return on Equity: -107.54%
Return on Assets: -91.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.13
Quick Ratio: 4.13

Sales & Book Value

Annual Sales: $260,000.00
Price / Sales: 52.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.78 per share
Price / Book: 1.18

Miscellaneous

Outstanding Shares: 6,480,000
Free Float: 5,162,000
Market Cap: $13.61 million
Optionable: Not Optionable
Beta: 1.19

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Milton H. Werner Ph.D. (Age 60)
CEO, President & Director
Comp: $697.96k
Mr. Garth Lees-Rolfe
Chief Financial Officer
Dr. Roger Rush
Head of Preclinical Research
Dr. Surendra Singh
Head of Chemistry, Manufacturing & Controls
Dr. Charles Warren Olanow B.Sc.
F.R.C.P.C., M.D., CEO of Clintrex Research Corporation & Member of Scientific Advisory Board
Dan Williams
Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IKT Stock Analysis - Frequently Asked Questions

Should I buy or sell Inhibikase Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibikase Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IKT shares.
View IKT analyst ratings or view top-rated stocks.
What is Inhibikase Therapeutics' stock price target for 2024?: 1 brokers have issued twelve-month price objectives for Inhibikase Therapeutics' shares. Their IKT share price targets range from $27.00 to $27.00. On average, they predict the company's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 1,185.7% from the stock's current price.
View analysts price targets for IKT or view top-rated stocks among Wall Street analysts.
How have IKT shares performed in 2024?: Inhibikase Therapeutics' stock was trading at $1.27 at the beginning of 2024. Since then, IKT shares have increased by 65.4% and is now trading at $2.10.
View the best growth stocks for 2024 here.
When is Inhibikase Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our IKT earnings forecast.

How were Inhibikase Therapeutics' earnings last quarter?: Inhibikase Therapeutics, Inc. (NYSE:IKT) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.15. Inhibikase Therapeutics had a negative net margin of 5,886.15% and a negative trailing twelve-month return on equity of 107.54%.
When did Inhibikase Therapeutics' stock split?: Inhibikase Therapeutics's stock reverse split before market open on Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.
When did Inhibikase Therapeutics IPO?: Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.
How do I buy shares of Inhibikase Therapeutics?: Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:IKT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Inhibikase Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Inhibikase Therapeutics Stock (NYSE:IKT)

IKT Stock Price History

IKT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

IKT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™